A randomised, double-blind, multicentre, phase III study to evaluate safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux oesophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d.
Study identifier:SH-NEP-0006
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised, double-blind, multicentre, phase III study to evaluate safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux oesophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d.
Medical condition
gastrointestinal diseases
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
